SCHEMBL4804575

SCHEMBL4804575

CCOc1cccc(C(=O)c2ccc(Br)cc2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.67
LMNA P02545 3/20 0.63
MAPK1 P28482 2/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
KMT2A Q03164 4/20 0.57
HPGD P15428 3/20 0.57
MEN1 O00255 2/20 0.57
MAPT P10636 2/20 0.57
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 1/20 0.57
ALOX15 P16050 1/20 0.57
ALOX12 P18054 1/20 0.57
RECQL P46063 1/20 0.57
HSD17B10 Q99714 1/20 0.57
MAOB P27338 3/20 0.56
MAOA P21397 1/20 0.56
AKR1C2 P52895 1/20 0.55
AKR1C1 Q04828 1/20 0.55
SRD5A2 P31213 1/20 0.52
RXRA P19793 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11003334 0.89 LMNA (0.78) TP53LMNAMAPK1L3MBTL1KMT2A
SCHEMBL5139133 0.89 HPGD (0.68) TP53LMNAMAPK1L3MBTL1KMT2A
SCHEMBL18917584 0.87 L3MBTL1 (0.75) LMNAMAPK1L3MBTL1KMT2AHPGD
SCHEMBL29161052 0.86 LMNA (0.65) TP53LMNAMAPK1L3MBTL1KMT2A
SCHEMBL30763329 0.86 LMNA (0.65) TP53LMNAMAPK1L3MBTL1KMT2A
SCHEMBL3468157 0.83 KMT2A (0.69) LMNAMAPK1L3MBTL1KMT2AHPGD
SCHEMBL31291512 0.83 KMT2A (0.69) LMNAMAPK1L3MBTL1KMT2AHPGD
SCHEMBL11578212 0.82 MAPK1 (0.68) LMNAMAPK1L3MBTL1KMT2AHPGD
Bromobenzene SCHEMBL27826021 0.82 KMT2A (0.63) TP53LMNAMAPK1L3MBTL1KMT2A
SCHEMBL21629496 0.81 ELANE (0.57) TP53LMNAMAPK1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345050-B2 Pyrimidine compounds ASTRAZENECA AB (SE) 2008-03-18 US disclosed
US-20040077642-A1 Pyrimidine compounds ASTRAZENECA AB (SE) 2004-04-22 US disclosed
EP-1373266-A2 (DIAZOLO-PYRIDINYL)-PYRIMIDINES FOR USE IN TREATMENT OF CNS DISORDERS AND DIABETES AstraZeneca AB (SE) 2004-01-02 EP disclosed
WO-2002065979-A2 (DIAZOLO-PYRIDINYL)-PYRIMIDINES FOR USE IN TREATMENT OF CNS DISORDERS AND DIABETES ASTRAZENECA AB (SE) 2002-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077642-A1 Pyrimidine compounds TYMP, DPYD, TYMS TP53 425/4885LMNA 1945/4885MAPK1 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.